Status:

COMPLETED

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women

Lead Sponsor:

Fred Hutchinson Cancer Center

Collaborating Sponsors:

Asociación Civil Impacta Salud y Educación, Peru

Asociación Civil Via Libre, Peru

Conditions:

HIV

Eligibility:

MALE

18+ years

Phase:

PHASE4

Brief Summary

This study will recruit men and transgender women with acute or recent HIV infection. It wil look at how HIV medicines (ART) when given very early after HIV infection affect the amount of HIV in the b...

Detailed Description

This is three-step study. Step 1 will screen men who have sex with men (MSM) and transgender women who are unaware of their HIV status and 1) report high risk behaviors for acquiring HIV-1 infection o...

Eligibility Criteria

Inclusion

  • Adult men who have sex with men, and transgender women
  • Unaware of HIV status at enrollment in follow-up cohort
  • High risk for HIV infection
  • Willing to test for HIV
  • No prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days
  • Willing to provide informed consent

Exclusion

  • Prior receipt of investigational anti-HIV vaccine
  • Ongoing therapy with any of the following:
  • Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed
  • Systemic chemotherapeutic agents
  • Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine
  • Immunomodulatory treatments including Interleukin-2
  • Investigational agents
  • Known allergy/sensitivity or any hypersensitivity to components of study drugs (ART) or their formulations
  • Active drug or alcohol use or dependence that would interfere with adherence to study requirements
  • Serious medical or psychiatric illness that would interfere with the ability to adhere to study requirements
  • Chronic or acute hepatitis B infection
  • Use of female hormonal products based on estrogen or derivatives

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2021

Estimated Enrollment :

225 Patients enrolled

Trial Details

Trial ID

NCT01815580

Start Date

July 1 2013

End Date

June 30 2021

Last Update

September 29 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Asociación Civil Impacta Salud y Educación

Lima, Peru

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women | DecenTrialz